NMP in myeloma [ 2014 - ]

Research Grant

Researchers: Prof David Ritchie (Principal investigator) ,  A/Pr Jake Shortt

Brief description We have newly discovered that a simple molecule called NMP has the ability to control myeloma cells that have become resistant to other available treatments. NMP works by enhancing immune function and by killing myeloma cells directly by inhibiting survival signals. NMP is different from all other types of available myeloma treatments. We intend to test the safety and power of NMP in the treatment of myeloma by running a clinical trial of NMP in patients with relapsed myeloma.

Funding Amount $533,599.00

Funding Scheme Project Grants

Notes Standard Project Grant